Recent studies show that most patients with X-linked hyper IgM syndrome have defects in the gene for CD40 ligand. We evaluated 17 unrelated males suspected of having Xlinked hyper IgM syndrome. Activated T cells from 13 of the 17 patients failed to bind a soluble CD40 construct. In these patients, the sequence of CD40 ligand demonstrated mutations. By contrast, T cells from the remaining four patients exhibited normal binding to the CD40 construct. Sequencing of the cDNA for CD40 ligand from these patients did not show mutations. The possibility that hyper IgM syndrome in these four patients was due to abnormalities in the B cell response to CD40-mediated signals was examined. Peripheral blood lymphocytes were stimulated with anti-CD40 alone, IL4 alone or anti-CD40 plus IL4. In comparison with B cells from controls or patients with hyper IgM syndrome and mutant CD40 ligand, B cells from the patients with hyper IgM syndrome and normal CD40 ligand were defective in their ability to secrete IgE (P < 0.02) or express activation markers, CD25 and CD23 (P < 0.02) in response to stimulation with anti-CD40. The failure of these B cells to respond to CD40-mediated activation could not be attributed to a generalized deficiency in B cell activation because IL4 induced normal up-regulation of CD23 and CD25 expression. These findings indicate that hyper IgM syndrome may result from defects in expression of CD40 ligand by activated T cells or defects in CD40-mediated
Introduction
Hyper IgM syndrome is a term used to describe a heterogeneous group of disorders characterized by normal or elevated concentrations of serum IgM but markedly decreased IgG, IgA and IgE (1) . Autosomal recessive, autosomal dominant, acquired, and X-linked forms have been described (2) (3) (4) (5) (6) . Although patients with X-linked hyper IgM syndrome have an early onset of infections and an increased incidence of neutropenia and opportunistic infections (2, 3), it is not always possible to distinguish the various forms of hyper IgM syndrome based on laboratory or clinical findings. Difficulties in making an accurate diagnosis are compounded by the fact that, as in all X-linked disorders that are lethal without medical intervention (7) , a third to half of the patients with X-linked hyper IgM syndrome will have no family history of immunodeficiency because they represent the first manifestation in their family of a new mutation.
Several laboratories have recently demonstrated that the Xlinked form of hyper IgM syndrome is caused by mutations in the gene for CD40 ligand (8) (9) (10) (11) (12) . CD40 ligand, which is also referred to as gp 39, is a Type II transmembrane protein with homology to TNF and nerve growth factor (13, 14) . It is expressed on the surface of activated T cells where it functions as a growth and differentiation factor, with particular specificity for B cells (15, 16) . Patients with X-linked hyper IgM syndrome have shown point mutations resulting in amino acid substitutions or altered splice sites and insertions or deletions in the gene for CD40 ligand (8) (9) (10) (11) (12) .
CD40 is a B cell surface antigen with homology to a family of growth factor receptors including CD27, CD30, and Fas, as well as TNF receptor and nerve growth factor receptor (17, 18) . Stimulation of B cells with CD40 ligand or antibodies to CD40 results in expression of B cell activation markers, short and long term proliferation, protection from apoptosis, and in the presence of cytokines, isotype switching (19) (20) (21) (22) . To (Table I) . When anti-CD40 was added to IL4 stimulated cultures, the amount of IgE secreted increased to a mean of 367,000 pg/ml. Although lymphocytes from patients with CD40 ligand negative hyper IgM syndrome did not secrete IgE in response to stimulation with IL4 alone (< 500 pg/ml), they did respond to EL4 plus anti-CD40 (67,000 pg/ml). By contrast, lymphocytes from the patients with CD40 ligand positive hyper IgM syndrome produced less than 5% of the amount of IgE secreted by controls in cultures stimulated either with IL4 alone (P < 0.02) or with ILA plus antibody to CD40 ligand (P < 0.01).
Expression of CD25 and CD23 in response to CD40 mediated stimulation. The those with normal CD40 ligand, we examined the past medical records of the patients and their similarly affected male relatives. Of the 13 patients with defects in CD40 ligand, four had affected maternal uncles or cousins and 3 had affected brothers, the remaining six patients were considered sporadic cases. One of the four patients with normal CD40 ligand (Patient 4) had affected relatives. This patient, who had hypohidrotic ectodermal dysplasia as well as hyper IgM syndrome, had a maternal half brother with both hypohidrotic ectodermal dysplasia and hyper IgM syndrome. He also had a maternal uncle who died of meningitis at one month of age. The concentrations of serum immunoglobulins in the patients with normal expression of CD40 ligand were not markedly different from those of patients with defects in CD40 ligand (Table II) . Although all patients had decreased serum IgA, concentrations of IgA > 10 mg/dl were detected at some time in 3 of the 5 patients with normal CD40 ligand and in 9 of the 15 patients with defects in CD40 ligand. Opportunistic infections were more common in the patients with defects in CD40 (26) showed that activated T cells from 13 of 31 patients with common variable immunodeficiency had decreased transcript for CD40 ligand and decreased surface expression of CD40 ligand as detected with a CD40 construct. Reduced expression of CD40 ligand correlated with low CD4/ CD8 ratios, decreased production of transcript for 1IL2, and in some patients, decreased expression of the activation marker, CD69. These findings indicate that reduced expression of CD40 ligand in these patients may be due to a more generalized defect in T cell function, although the gene for CD40 ligand was not sequenced in any of these patients. Two of the patients included in our study had been previously diagnosed as having common variable immunodeficiency because they did not have elevated serum IgM, a history of opportunistic infections or neutropenia. T cells from both patients had normal expression of the activation marker, CD25, but failed to bind CD40 construct. Both had mutations in the gene for CD40 ligand. The use of a CD40 construct as diagnostic tool will require appropriate controls to verify normal T cell activation.
B cells from CBA/N mice fail to proliferate in response to anti-CD40; however, they do upregulate CD23 expression (27) . Similar defects have not been reported in humans. The group that demonstrated reduced expression of CD40 ligand on activated T cells from some patients with common variable immunodeficiency reported normal B cell proliferation and IgE production in response to IL4 and anti-CD40 stimulation in 22 patients with this disorder (28). Although B cells from all four of our patients with hyper IgM syndrome and normal CD40 ligand demonstrated measurable production of IgE in response to anti-CD40 stimulation, these responses were always < 5% of the control cultures analyzed in parallel. By contrast, upregulation of CD23 expression in response to IL4 stimulation was normal or increased in the three patients studied, suggesting that the decreased response to anti-CD40 was not due to a generalized B cell insensitivity to activation signals.
The identification of CD40 ligand as the defective gene in X-linked hyper IgM syndrome permits better characterization not only of this disorder, but of other disorders that are phenotypically similar. A better understanding of these disorders is a prerequisite for therapeutic interventions such as gene therapy. These studies will also help elucidate normal T cell-B cell interactions and activation pathways.
